文献速递乳腺癌

循环肿瘤DNA分析追踪转移性乳腺癌芳香化酶抑制剂耐药演变

Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer.
PubMed 文献 · Ann Oncol · 2018-01-01

39例进展患者中56.4%可检出ESR1突变,中位提前6.7个月可检测到,72.2%为亚克隆;KRAS突变在进展患者中占15.4%,SoFEA队列中为21.2%但无预后证据。

要点

  • 一线AI进展患者中56.4%(22/39)可检出ESR1突变,40.9%(9/22)为多克隆。
  • ESR1突变中位提前6.7个月(95%CI 3.7-NA)可于临床进展前检测到。
  • 进展血浆eTAm-Seq显示ESR1突变72.2%(13/18)为亚克隆,KRAS突变占15.4%(6/39)。

核心结论

  • 一线AI进展的乳腺癌呈现高度遗传异质性,常见亚克隆突变。
  • 亚克隆KRAS突变检出频率较高,AI耐药肿瘤的遗传多样性可能限制后续靶向治疗策略。

研究设计与样本

  • ctDNA采用微滴数字PCR和增强标记扩增子测序(eTAm-Seq)分析,并在SoFEA试验独立队列中验证基线血浆样本。

主要发现

  • 39例一线AI进展患者中,56.4%(22/39)在进展时可检出ESR1突变,其中40.9%(9/22)为多克隆。
  • 连续追踪显示ESR1突变中位提前6.7个月(95%CI 3.7-NA)于临床进展被检出。
  • 进展血浆eTAm-Seq测序显示ESR1突变在72.2%(13/18)患者中为亚克隆。
  • 进展患者中RAS基因突变占15.4%(6/39),包括4例KRAS、1例HRAS、1例NRAS。
  • SoFEA队列中KRAS突变检出率为21.2%(24/113),但无证据表明KRAS突变状态对无进展生存或总生存有预后价值。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Selection of resistance mutations may play a major role in the development of endocrine resistance. ESR1 mutations are rare in primary breast cancer but have high prevalence in patients treated with aromatase inhibitors (AI) for advanced breast cancer. We investigated the evolution of genetic resistance to the first-line AI therapy using sequential ctDNA sampling in patients with advanced breast cancer. PATIENTS AND METHODS: Eighty-three patients on the first-line AI therapy for metastatic breast cancer were enrolled in a prospective study. Plasma samples were collected every 3 months to disease progression and ctDNA analysed by digital droplet PCR and enhanced tagged-amplicon sequencing (eTAm-Seq). Mutations identified in progression samples by sequencing were tracked back through samples before progression to study the evolution of mutations on therapy. The frequency of novel mutations was validated in an independent cohort of available baseline plasma samples in the Study of Faslodex versus Exemestane with or without Arimidex (SoFEA) trial, which enrolled patients with prior sensitivity to AI. RESULTS: Of the 39 patients who progressed on the first-line AI, 56.4% (22/39) had ESR1 mutations detectable at progression, which were polyclonal in 40.9% (9/22) patients. In serial tracking, ESR1 mutations were detectable median 6.7 months (95% confidence interval 3.7-NA) before clinical progression. Utilising eTAm-Seq ctDNA sequencing of progression plasma, ESR1 mutations were demonstrated to be sub-clonal in 72.2% (13/18) patients. Mutations in RAS genes were identified in 15.4% (6/39) of progressing patients (4 KRAS, 1 HRAS, 1 NRAS). In SoFEA, KRAS mutations were detected in 21.2% (24/113) patients although there was no evidence that KRAS mutation status was prognostic for progression free or overall survival. CONCLUSIONS: Cancers progressing on the first-line AI show high levels of genetic heterogeneity, with frequent sub-clonal mutations. Sub-clonal KRAS mutations are found at high frequency. The genetic diversity of AI resistant cancers may limit subsequent targeted therapy approaches.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Fribbens C, Garcia Murillas I, Beaney M, et al. Tracking evolution of aromatase inhibitor resistance with circulating tumour DNA analysis in metastatic breast cancer. Ann Oncol. 2018. PMID: 29045530. doi:10.1093/annonc/mdx483

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。